4basebio PLC
4BB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 94% | 84.5% | 22.4% | – |
| Gross Profit | £0 | -£0 | £0 | £0 |
| % Margin | 10.7% | -4.3% | 72% | 66.8% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -615.9% | -1,314.4% | -1,667.1% | -1,530.6% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -664.7% | -1,091.7% | -1,746.3% | -1,533.6% |
| EPS Diluted | -0.5 | -0.51 | -0.45 | -0.33 |
| % Growth | 2% | -13.3% | -36.4% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |